Edition:
India

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

79.45EUR
5:24pm IST
Change (% chg)

€-0.20 (-0.25%)
Prev Close
€79.65
Open
€79.55
Day's High
€80.00
Day's Low
€79.25
Volume
14,867
Avg. Vol
80,315
52-wk High
€82.10
52-wk Low
€53.70

Select another date:

Mon, Jan 8 2018

BRIEF-Qiagen, DiaSorin partner in automated tuberculosis detection

* SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​

BRIEF-Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis

* ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS

BRIEF-Diasorin Receives CE Mark For A New Bordetella Molecular Diagnostic Test

* RECEIVES CE MARK FOR A NEW BORDETELLA MOLECULAR DIAGNOSTIC TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance

* Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO

BRIEF-Diasorin revises its FY 2019 guidance

* INCREASES ITS 2019 REVENUE GUIDANCE TO ABOUT EUR 775 MILLION FROM EUR 735 MILLION

BRIEF-DiaSorin ‍completes acquisition of Elisa immunodiagnostic business portfolio​

* ‍COMPLETES ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin ‍earns CE-mark extending sample claims for its Simplexa HSV 1&2 kit​

* ‍EARNS CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR'S SIMPLEXA HSV 1 & 2 KIT​

BRIEF-DiaSorin Q2 net profit up at EUR 33.6 mln

* Q2 NET PROFIT EUR 33.6 MILLION VERSUS EUR 29.4 MILLION YEAR AGO

BRIEF-DiaSorin launches three primer pairs for use in molecular testing

* LAUNCHES 3 PRIMER PAIRS FOR USE IN MOLECULAR TESTING: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, AND GROUP G STREPTOCOCCUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Diasorin to acquire ELISA immunodiagnostic business portfolio from Siemens Healthineers

* TO ACQUIRE ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS

Select another date: